Mankind Pharma Ltd
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory d… Read more
Mankind Pharma Ltd (MANKIND) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.022x
Based on the latest financial reports, Mankind Pharma Ltd (MANKIND) has a cash flow conversion efficiency ratio of 0.022x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹1.93 Billion) by net assets (₹86.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mankind Pharma Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Mankind Pharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mankind Pharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mankind Pharma Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hainan Mining Co Ltd
SHG:601969
|
0.076x |
|
ASR Microelectronics Co. Ltd. A
SHG:688220
|
N/A |
|
Fortress Transportation and Preferred Series B
NASDAQ:FTAIO
|
-0.514x |
|
Provident Financial Services Inc
NYSE:PFS
|
0.035x |
|
Interpump Group S.p.A.
LSE:0EWD
|
0.080x |
|
Scorpio Tankers Inc
NYSE:STNG
|
0.044x |
|
Guangdong HongDa Blasting Co Ltd
SHE:002683
|
0.001x |
|
Wanxiang Qianchao Co Ltd
SHE:000559
|
0.062x |
Annual Cash Flow Conversion Efficiency for Mankind Pharma Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Mankind Pharma Ltd from 2019 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹145.68 Billion | ₹24.13 Billion | 0.166x | -26.30% |
| 2024-03-31 | ₹95.76 Billion | ₹21.52 Billion | 0.225x | -5.18% |
| 2023-03-31 | ₹76.49 Billion | ₹18.13 Billion | 0.237x | +62.80% |
| 2022-03-31 | ₹63.16 Billion | ₹9.20 Billion | 0.146x | -37.73% |
| 2021-03-31 | ₹48.63 Billion | ₹11.37 Billion | 0.234x | -19.73% |
| 2020-03-31 | ₹36.72 Billion | ₹10.70 Billion | 0.291x | +44.69% |
| 2019-03-31 | ₹29.82 Billion | ₹6.00 Billion | 0.201x | -- |